

Author, year	N; mean age (range)	Etiology n (%)			Follow up, mean (range)	Outcome	Determinants of adverse outcome
		Immune complex	Pauci- immune GN	Anti- GBM			
Dewan [1], 2008	22; 12.3 (4-18) yr	19 (86.4): post-infectious GN (7), IgA nephropathy (3), membranoproliferative GN (3), SLE (2), others (4)	1 (4.6)	2 (9.1)	8.1 (1-43) mo	Mean renal survival 14.4 months. Proteinuria, 13; CKD 1-3, 7; CKD 4, 3; CKD 5, 10 <sup>*1</sup>	Fibrocellular crescents, glomerular sclerosis
Jardim [2], 1992	30; 9.5 (3.7-15.7) yr	19 (63.3): Henoch Schonlein pur- pura (9), membranoproliferative GN (7), poststreptococcal GN (2), SLE (1)	5 (16.7)	2 (6.7)	2.0 (0.1-9.5) yr	eGFR >80 ml/min/1.73 m <sup>2</sup> , 4; eGFR 30-80, 6; eGFR 15-30, 4; eGFR <15, 16 (includes 3 deaths)	Dialysis at presentation; fibrous crescents; time to treatment
Southwest Pediatric Nephrology Study Group [3], 1985	50; 10.1 (1.7- 17.2) yr	37 (74): unspecified (13), SLE (9), poststreptococcal GN (6), IgA nephropathy or Henoch Schölein purpura (7), membranoproliferative GN (2)	10 (20) <sup>#</sup>	3 (6)	NA	ESRD, 23; eGFR <60, 6; eGFR >60, 18; proteinuria, 12; hypertension, 4; hematuria, 1 <sup>*2</sup>	Large, cellular/fibrous crescents; IgM deposits; gaps in Bowman capsule; interstitial fibrosis, tubular atrophy, glomerulosclerosis
Tapaney-Olarn [5], 1992** <sup>1</sup>	16; NA (1-14) yr	Poststreptococcal GN (6), SLE (1)	—	—	—	ESRD, 8; complete or partial recovery, 8	Idiopathic; extensive (>80%) crescents
Srivastava [4], 1992** <sup>2</sup>	43; 8.7 (3.5-14) yr	Poststreptococcal GN (11), Henoch Schönlein purpura (3), juvenile rheumatoid arthritis (1), SLE (1)	1	—	—	ESRD, 23; renal insufficiency 14; recovery, 6	Need for dialysis
Miller [14], 1984** <sup>3,^</sup>	56; 1.3-17 yr	SLE (10), membranoproliferative GN (17), IgA nephropathy or Henoch Schölein purpura (11), poststreptococcal GN (2)	1	—	3.1 (0-12) yr	Renal failure, 19; renal insufficiency, 3; normal function, 20; not available 14	Membranoproliferative GN; idiopathic disease Improved, 30; dialysis
Isaad [7], 2011** <sup>4</sup>	37; 13.2±5.6	SLE (20), postinfectious GN (6), others (5)	3	—	30.9±22 mo	Improved 30; dialysis dependent, 7	Young age, non-SLE; proportion with crescents, tubular necrosis, vasculopathy
Present report, 2012	36; 10 <sup>\$</sup> (8-11.5) yr	17 (47.2): SLE (4), postinfectious GN (3), membranoproliferative GN (2), IgA nephropathy (2), Henoch Schonlein purpura (2), idiopathic (5)	19 (52.8)	0	34 <sup>\$</sup> (19-72)	Normal renal function, 7; abnormal urinalysis or hypertension, 12; CKD 3, 7; CKD 4-5, 10	Dialysis or oliguria at presentation; (inverse association with) normal glomeruli

\*Outcome not reported for <sup>1</sup>2 and <sup>2</sup>3 patients; \*\*Did not distinguish pauci-immune GN as distinct category; disease termed idiopathic in <sup>1</sup>9, <sup>2</sup>26, <sup>3</sup>11 and <sup>4</sup>3 patients; <sup>#</sup>Includes 3 vasculitis and 7 idiopathic without immune deposits; <sup>^</sup> Includes Alport (3) and hemolytic uremic syndrome (1); <sup>\$</sup> Median value; CKD chronic kidney disease; eGFR estimated glomerular filtration rate (ml/1.73 m<sup>2</sup>/minute); GN glomerulonephritis; NA not available; SLE systemic lupus erythematosus.